Clinical Trial Goal
To find out:
- The highest dose of QXL138AM that's safe to give
- If QXL138AM is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have been treated with all of the following (your doctor can tell you this):
- A drug that targets CD38
- An IMiD
- A Proteosome inhibitor
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
QXL138AM is an interferon alpha 2 (IFNa2) masked immunocytokine (MIC) that is fused to an antibody that targets CD138.
You’ll get:
You’ll get:
- QXL138AM – Given as intravenous (IV) infusions 1 time every 2 weeks
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for 3.5 years.
The Food and Drug Administration (FDA) has not yet approved QXL138AM.
Locations
Sponsors
lead: Nammi Therapeutics Inc
